IJCS | Volume 33, Nº4, July and August 2020

400 24. Birnie DH. Comparing and Contrasting Guidelines for the Diagnosis of Cardiac Sarcoidosis. Ann Nucl Cardiol. 2017;3(1):46-7. 25. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014; 11(7):1304-23. 26. Sharma A, Okada DR, Yacoub H, Chrispin J, Bokhari S. Diagnosis of cardiac sarcoidosis: an era of paradigm shift. Ann Nucl Med. 2019; 1-7. 27. Kawakatsu N, Suzuki A, Serizawa N, Suzuki T, Ejima K, Shiga T, et al. Isolated cardiac sarcoidosis diagnosed by electroanatomic voltage mapping-guided endomyocardial biopsy combined with magnetic resonance imaging and positron emission tomography. J Cardiol Cases. 2016;14(4):107-10. 28. Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L, et al. The WASOG sarcoidosis organ assessment instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffus Lung Dis. 2014;31(1):19-27. 29. Kouranos V, Tzelepis GE, Rapti A, Mavrogeni S, Aggeli K, Douskou M, et al. Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2017;10(12):1437-47. 30. Silberstein EB, DeVries DF. Reverse redistribution phenomenon in thallium-201 stress tests: Angiographic correlation and clinical significance. J Nucl Med. 1985;26(7):707-10. 31. Hirose Y, Ishida Y, Hayashida K, Maeno M, Takamiya M, Ohmori F, et al. Myocardial involvement in patients with sarcoidosis: An analysis of 75 patients. Clin Nucl Med. 1994;19(6):522-6. 32. Ramirez R, Trivieri M, Fayad ZA, Ahmadi A, Narula J, Argulian E. Advanced imaging in cardiac sarcoidosis. J Nucl Med. 2019;60(7):892-8. 33. Smedema JP, Snoep G, Van Kroonenburgh MPG, Van Geuns RJ, Dassen WRM, Gorgels APM, et al. Evaluation of the accuracy of gadolinium- enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45(10):1683-90. 34. Ichinose A, Otani H, Oikawa M, Takase K, Saito H, Shimokawa H, et al. MRI of cardiac sarcoidosis: Basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. Am J Roentgenol. 2008;191(3):862-9. 35. BravoPE,SinghA,DiCarliMF,BlanksteinR.Advancedcardiovascularimaging for the evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2019; 26(1):188-99. 36. Juneau D, Erthal F, Ohira H, Mc Ardle B, Hessian R, de Kemp RA, et al. Clinical PET Myocardial Perfusion Imaging and Flow Quantification. Cardiol Clin. 2016;34:69-85. 37. Keida T, Ohira H, Fujita M, Chinen T, Nakamura K, Kato T, et al. Quantitative assessment of dyssynchrony using ECG-gated SPECT myocardial perfusion imaging prior to and following cardiac resynchronization therapy. Circ J. 2009;73(8):1550–3. 38. Ise T, Hasegawa T, Morita Y, Yamada N, Funada A, Takahama H, et al. Extensive late gadolinium enhancement on cardiovascular magnetic resonancepredictsadverseoutcomesandlackofimprovementinLVfunction after steroid therapy in cardiac sarcoidosis. Heart. 2014;100(15): 1165-72. 39. Schieda N, Blaichman JI, CostaAF, Glikstein R, Hurrell C, James M, et al. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Canad Assoc Radiol J. 2018;69(2):136-50. 40. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26(15):1538-43. 41. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18 F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45(12):1989-98. 42. Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, EinsteinAJ, GoldmanM, et al. Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing. Chest. 2008;133(6):1426-35. 43. Newsholme P, Newsholme EA. Rates of utilization of glucose, glutamine and oleate and formation of end-products bymouse perioneal macrophages in culture. Biochem J. 1989;261(1):211-8. 44. IsiguzoM, Brunken R, Tchou P, XuM, Culver DA. Metabolism-perfusion imaging to predict disease activity in cardiac sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis. 2011;28(1):50-5. 45. Treglia G, Taralli S, Mattoli MV, Giordano A. Utility of whole-body Fluorine-18-fluorodeoxyglucose positron emission tomography in patients with sarcoidosis. In: Medical Imaging: Procedures, Techniques and Applications, 2012. p.39-50. 46. Chareonthaitawee P, Beanlands RS, ChenW, Dorbala S, Miller EJ, Murthy VL, et al. Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in carDiac sarcoid detection and therapy monitoring writing group. J Nucl Med. 2017;58(8):1341-53. 47. Skali H, Schulman AR, Dorbala S. 18 F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep. 2013;15(5):352. 48. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53(2):241-8. 49. Kim SJ, Pak K, Kim K. Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; A systematic review andmeta-analysis. J Nucl Cardiol. 2019 Jan 2. doi: 10.1007/s12350-018-01582-y online ahead of print. 50. Sgard B, Brillet PY, Bouvry D, Djelbani S, Nunes H, Meune C, et al. Evaluation of FDG PET combined with cardiac MRI for the diagnosis and therapeutic monitoring of cardiac sarcoidosis.  Clinical radiology . 2019;  74 (1):81-e9. 51. Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2014;21(5):925-39. 52. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014; 63(4):329-36. 53. Osborne MT, Hulten EA, Murthy VL, Skali H, Taqueti VR, Dorbala S, et al. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J Nucl Cardiol. 2017; 24(1):86-99. 54. Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014; 21 (1):166-74. 55. Farber G, Boczar K, Wiefels C, Zelt J, Guler EC, DeKemp RA ,et al. The future of cardiac molecular imaging. Semin Nucl Med. 2020.00:1-19. 56. Wisenberg G, Thiessen JD, Pavlovsky W, Butler J, Wilk B, Prato FS. Same day comparison of PET/CT and PET/MR in patients with cardiac sarcoidosis.  J Nucl Cardiol. 2019. https//:doi:.org/1a1007/ s12350-018-01578-8. 57. Birnie D, Beanlands RSB, Nery P, Aaron SD, Culver DA, DeKemp RA, et al. Cardiac Sarcoidosismulti-center randomized controlled trial (CHASM CS- RCT). Am Heart J. 2019;220( ):246–52 58. Blankstein R, Waller AH. Evaluation of Known or Suspected Cardiac Sarcoidosis. Circ Cardiovasc Imaging. 2016;9(3):e000867. 59. Alvi RM, Young BD, Shahab Z, Pan H, Winkler J, Herzog E, et al. Repeatability and Optimization of FDG Positron Emission Tomography for Evaluation of Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2019;12(7 Pt1):124-7. 60. NingN, GuoHH, IagaruA, Mittra E, Fowler M, Witteles R. Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients With Cardiac Sarcoidosis. J Card Fail. 2019;25(4):307-11. Wiefels et al. 18F-FDG PET/CT and cardiac sarcoidosis Int J Cardiovasc Sci. 2020; 33(4):389-400 Review Article This is an open-access article distributed under the terms of the Creative Commons Attribution License